Read this company snapshot
Daily valuation snapshot
Tarsus Pharmaceuticals, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $73.16
- Market capitalization (USD)
- $3,210,479,987.36
- Price / earnings (TTM)
- Not reported
- Price / book
- 9.26
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research TARS in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research TARS in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing TARS with another company.
| Daily close (USD) | $73.16 |
| Market capitalization (USD) | $3,210,479,987.36 |
| Price / earnings (TTM) | Not reported |
| Price / book | 9.26 |
No matching rows. Clear the filter to see all records.
Read TARS's valuation metrics
Company size
Tarsus Pharmaceuticals, Inc. Common Stock's recorded market capitalization is $3,210,479,987.36. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
TARS's recorded price-to-book ratio is 9.26. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Tarsus Pharmaceuticals, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about TARS. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow TARS's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.